Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

ABSTRACT:

Background

Loss of bronchoprotection (LOBP) with a regularly used long-acting β₂-adrenergic receptor agonist (LABA) is well documented. LOBP has been attributed to β₂-adrenergic receptor (B2AR) downregulation, a process requiring farnesylation, which is inhibited by alendronate.

Objective

We sought to determine whether alendronate can reduce LABA-associated LOBP in inhaled corticosteroid (ICS)-treated patients.

Methods

We conducted a randomized, double-blind, placebo-controlled, parallel-design, proof-of-concept trial. Seventy-eight participants with persistent asthma receiving 250 μg of fluticasone twice daily for 2 weeks were randomized to receive alendronate or placebo while initiating salmeterol for 8 weeks. Salmeterol-protected methacholine

SUBMITTER: Cardet JC 

PROVIDER: S-EPMC6950766 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature